Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remdesivir - Gilead Sciences

Drug Profile

Remdesivir - Gilead Sciences

Alternative Names: Captisol-enabled remdesivir; Captisol®-enabled GS 5734; GS-5734; Veklury

Latest Information Update: 07 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer China-Japan Friendship Hospital; Gilead Sciences; INSERM; National Institute of Allergy and Infectious Diseases; NeuroActiva; Quantum Leap Healthcare Collaborative; Roche
  • Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Phosphorus compounds; Pyridazines; Pyrroles; Small molecules; Triazines
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections
  • Phase III Pneumonia
  • Phase II Adult respiratory distress syndrome; Ebola virus infections
  • Phase I Neurological disorders

Most Recent Events

  • 04 Aug 2020 Phase-II clinical trials in Adult respiratory distress syndrome (Combination therapy) associated with COVID-19 infections in USA (IV) (NCT04488081)
  • 29 Jul 2020 Gilead Sciences plans to launch remdesivir in the EU on emergency use basis in August 2020
  • 23 Jul 2020 Phase-II/III clinical trials in COVID-2019 infections (In adolescents, In children, In infants, In neonates, In adults) in United Kingdom (IV) (EudraCT2020-001803-17)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top